(Q38443954)

English

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

scientific article published on 11 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Tamas Hickish

15

0 references

object named as

Stephen Chan

13

0 references

object named as

Janet A Dunn

3

0 references

object named as

Helena M Earl

1

0 references

19

object named as

Carlos Caldas

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

7

object named as

Jean Abraham

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Louise Hiller

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Clare Blenkinsop

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Louise Grybowicz

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Anne-Laure Vallier

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Jeremy Thomas

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Elena Provenzano

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Luke Hughes-Davies

10

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Ioannis Gounaris

11

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Karen McAdam

12

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Rizvana Ahmad

14

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Stephen Houston

16

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Daniel Rea

17

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

John Bartlett

18

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

David A Cameron

20

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Larry Hayward

21

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

ARTemis Investigators

22

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

11 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

656-666

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting of adjuvant breast cancer trials: when is the right time?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Fighting fire with fire: rekindling the bevacizumab debate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and accelerated drug approval in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970137-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70137-3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38443954&oldid=1766861600"